Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dmitri Alperovitch, Silverado Policy executive chairman, joins ‘Fast Money’ to talk about the SEC’s page on ‘X’ being hacked and the implications of the hack on the bitcoin market. 05:03 Tue, Jan 9 20246:10 PM EST
CNBC’s Jim Cramer told investors about a potentially bullish tell: Watch for when management buys back shares of a stock with high short interest. A short position is created when an investor sells shares they borrowed with the expectation that they will decrease in value. If the stock falls, the investor can buy the shares…
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email David George, Baird senior analyst, joins ‘Fast Money’ to talk his bearish calls on banks ahead of another round of earnings. 03:38 Mon, Jan 8 20246:16 PM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fred Thiel, Marathon Digital CEO and Mike Belshe, Bitgo CEO, joins ‘Closing Bell Overtime’ to talk the kick off of spot bitcoin ETF trading after SEC approval.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
Grayscale CEO Michael Sonnenshein joins ‘Squawk Box’ to discuss the SEC’s approval of bitcoin ETFs, the long road to regulatory approval, what it means for Grayscale and crypto at large going forward, and more.